Comparator report on patient access to cancer medicines in Europe revisited - A UK perspective

The report, authored by world-leading economists at Sweden’s Institute of Health Economics as a follow up to a 2009 Europe-wide cancer comparator project, compares the uptake and access environment for cancer medicines in the UK and relative increasing burden of cancer. “Please note: In this report, ‘ipulimimab’ should be spelled ‘ipulimumab’. This will be updated in a future version of the report.”